Greater Glasgow and Clyde Medicines

Click here to access the full blog

New HEPMA oral antibiotic protocols for non-severe respiratory and urinary tract infections with no previous intravenous (IV) antibiotic treatment have been introduced to support prescribing and improve documentation of oral antibiotic stop dates on HEPMA. 

Click here to access the full blog

• Medicines Update blogs have been presented in Microsoft Sway format since August 2023.
• Some users prefer alternative formats for reading, such as Word or PDF, or benefit from accessibility features like immersive reader/read aloud.
• Sways can be read aloud, viewed in accessibility view, or exported to Word or PDF. These options enable users to choose their preferred format to enhance readability and accessibility.

Click here to access the full blog

Click here to access the full blog

Click here to access the full blog

• Two adrenaline auto-injector (AAI) devices should always be prescribed and supplied.
• Patients should carry two in-date AAI devices at all times.
• Patients and their carers should be trained on their particular device, as injection technique varies between brands (Epipen®, Jext®).

Click here to access the full blog

Click here to access the full blog

• GMAWS is effective in managing alcohol withdrawal syndrome (AWS).
• The 2025 revised guidance allows easier estimation of alcohol units consumed.
• The Fast Alcohol Screening Tool (FAST) score is used to assess use disorder: a score of 5 or more suggests alcohol dependency.
• Prevention and treatment of Wernicke’s encephalopathy refers to ‘Vitamins B&C solution’ for intravenous infusion. Pabrinex® is no longer routinely available.
• The treatment of those at risk of Wernicke’s encephalopathy has been simplified.
• Oral thiamine should be continued for at least 6 weeks after becoming abstinent and having established a satisfactory diet. At that point thiamine discontinuation should be considered.
• Senior medical review of diagnosis and the need for possible adjunctive therapy if the patient:
• requires more than 120mg diazepam (or 12mg lorazepam) in 24 hours or
• is requiring full dose treatment 96 hours after last alcohol ingestion.
• Alterations to AWS treatment for patients with liver disease have been more clearly defined (see further details in Background section):
• All patients with evidence of advanced liver disease (cirrhosis) use symptom triggered treatment only.
• Patients with evidence of advanced liver disease and liver dysfunction: jaundice (bilirubin >80micromol/l), coagulopathy (INR/Prothrombin time ratio >1.5) or history of hepatic encephalopathy: use symptom triggered lorazepam: 1mg-2mg.

Click here to access the full blog

• Cardiovascular diseases cause more than a quarter of all deaths in Scotland, the second most common cause of death after cancer.

• The Cardiovascular Risk Factors Programme, launched in April 2025, aims to address this challenge with the goal of reducing avoidable premature CVD deaths by 20% in 20 years.

• To support implementation of the programme a 'National cardiovascular disease (CVD) prevention and risk factors toolkit' has been created on the Right Decision Service website.
  

Click here to access the full blog

• Mixing polyethylene glycol/macrogol laxatives (e.g. Laxido®, Movicol®) with starch-based thickeners (see table in blog) poses a risk to patients with dysphagia.
• Combining the two compounds results in a thinner, watery fluid, increasing the risk of aspiration.
• Action is required to ensure that patients are not using a starch-based thickener in combination with a macrogol laxative (see recommendations in blog).
• The current preferred list first line thickening product in NHSGGC is xanthan gum-based Nutilis® Clear which can be used with macrogol laxatives.

Click here to access the full blog